Therapeutic effectiveness of upadacitinib combined with glucocorticoid on remission induction and maintenance in giant cell arteritis

A Sanada, N Abe, M Bohgaki, H Kasahara - Rheumatology, 2022 - academic.oup.com
DEAR EDITOR, Large-vessel vasculitis (LVV) typically refers to the inflammatory disease of
large blood vessels, predominantly affecting the aorta and its major branches. LVV is …

Anti-cytokine treatment for Takayasu arteritis: state of the art

E Tombetti, MC Di Chio, S Sartorelli… - Intractable & rare …, 2014 - jstage.jst.go.jp
Takayasu arteritis (TA) is a rare and idiopathic large-vessel arteritis typically affecting young
women which has important morbidity and mortality. There are no animal models of TA and …

Current diagnosis and management of Takayasu arteritis

D Danda - International Heart Journal, 2023 - jstage.jst.go.jp
Takayasu arteritis (TA or TAK) is a chronic large vessel vasculitis with predilection to affect
the aorta and its branches. The new 2022 ACR/EULAR classification criteria for Takayasu …

Tocilizumab in refractory Caucasian Takayasu's arteritis: a multicenter study of 54 patients and literature review

D Prieto-Peña, P Bernabeu, P Vela… - Therapeutic …, 2021 - journals.sagepub.com
Objective: To assess the efficacy and safety of tocilizumab (TCZ) in Caucasian patients with
refractory Takayasu's arteritis (TAK) in clinical practice. Methods: A multicenter study of …

Effects of glucocorticoids and tumor necrosis factor-alpha inhibitors on both clinical and molecular parameters in patients with Takayasu arteritis

R Serra, R Grande, G Buffone… - Journal of …, 2014 - journals.sagepub.com
Objective: To explore the effect of sequential treatment with glucocorticoid and tumor
necrosis factor-alpha inhibitors in patients with Takayasu arteritis (TA). Materials and …

Efficacy and safety of anti–interleukin 6 receptor monoclonal antibody (tocilizumab) in Colombian patients with Takayasu arteritis

CA Cañas, F Cañas, JH Izquierdo… - JCR: Journal of …, 2014 - journals.lww.com
Purpose The aim of this study was to describe the efficacy and safety of anti–interleukin 6
receptor antibody (tocilizumab [TCZ]) in patients with severe or refractory Takayasu arteritis …

Management of Takayasu arteritis: a systematic review

G Keser, H Direskeneli, K Aksu - Rheumatology, 2014 - academic.oup.com
Assessment of the pattern and extent of arterial involvement and measurement of current
disease activity are essential for the management of Takayasu arteritis (TA). Since there is …

Long-term outcome of 251 patients with Takayasu arteritis on combination immunosuppressant therapy: single centre experience from a large tertiary care teaching …

R Goel, D Danda, G Joseph, R Ravindran… - Seminars in arthritis and …, 2018 - Elsevier
Introduction Long-term outcome studies in Takayasu arteritis (TA) are few and limited by
small sample size. In this study, we analysed the outcome of treatment in a large series of TA …

Takayasu's arteritis: a case with relapse after urgent coronary revascularization

K Empen, A Hummel, D Beug, SB Felix, MC Busch… - BMC Research …, 2017 - Springer
Background Vasculitides are commonly unrecognized causes of coronary stenosis and
myocardial ischemia. We report on a 24-year old patient with Takayasu's arteritis who …

Treatment of large vessel vasculitis

MA Alba, G Espígol-Frigolé, M Butjosa… - Current Immunology …, 2011 - ingentaconnect.com
Giant-cell arteritis (GCA) and Takayasu's arteritis (TAK) are chronic and relapsing
inflammatory diseases involving large and medium sized arteries. While symptoms derived …